Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
about the author
Brittany Meiling
editors@endpointsnews.com
Brittany Meiling on LinkedIn
author articles
Grail vet Bajaj aims for some broad influence with Foresite bucks
8 years ago
Peer Review
Watch out Merck: Heron snagged FDA approval on Emend competitor
8 years ago
Pharma
Inching closer to blockbuster status, Seattle Genetics gets fourth FDA win for Adcetris
8 years ago
Pharma
Ex-Shire exec Phil Vickers joins the migration to startups, taking the reins at an immuno-oncology biotech
8 years ago
People
Hunting for early-stage life sciences bets, Partners Healthcare closes $171M for venture fund
8 years ago
Financing
Sanofi bolsters its position on multiple sclerosis with a $765M BTK licensing deal
8 years ago
Pharma
Exodus of Ex-Googlers at Silicon Valley's sexiest biotech startups
8 years ago
People
German biotech InflaRx raises $100M in IPO
8 years ago
Financing
Amgen bets on stem cell company Fortuna Fix in $25M round
8 years ago
Financing
R&D
Who are the top 10 players that dominate the cancer drug market? And who's growing fastest?
8 years ago
R&D
Pharma
Watch out Sanofi: Takeda's new data on dengue vaccine is good news for PhIII trial
8 years ago
R&D
The Department of Defense could undermine FDA, giving the green light for experimental products
8 years ago
Pharma
Amgen is shaking up R&D (again), chopping 200 as Genentech targets 130 layoffs
8 years ago
R&D
Pharma
Peer Review: aTyr promotes data expert Sanjay Shukla as CEO
8 years ago
Peer Review
Is Neurocrine primed for takeover? Revenue soars on Ingrezza sales
8 years ago
Pharma
Novartis and Amgen launch new Alzheimer's study
8 years ago
R&D
Discovery
IPO market warms with Spero, Allena heading to Wall Street
8 years ago
Financing
Dicerna and Boehringer partner on RNAi treatment for NASH
8 years ago
R&D
Shkreli out, Cuban in: Twitter proves essential for biotech rebel Ethan Perlstein
8 years ago
People
Financing
FDA panel votes yes on Indivior’s opioid addiction drug
8 years ago
Pharma
California upstart Xyphos wants to tackle CAR-T's big problems
8 years ago
Startups
Discovery
Neos considering offers after rejecting PDL’s $300M bid: Reuters
8 years ago
Deals
AstraZeneca gets an early green light on BTK blockbuster hopeful Calquence
8 years ago
Pharma
Expanding its preclinical attack on Duchenne MD, Sarepta grabs a license for Duke's CRISPR tech
8 years ago
Discovery
First page
Previous page
14
15
16
17
18
Next page
Last page
